Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium

Journal of Steroid Biochemistry and Molecular Biology

Volumn 84, Issue 4, 2003, Pages 469-478

  Jensen, Janne ^a   Kitlen, Jason W ^a   Briand, Per ^a   Labrie, Fernand ^b   Lykkesfeldt, Anne E ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

4 OH androstenedione; Antiestrogens; Aromatase inhibitor; Breast cancer; EM 652; Estrogen receptor ; Growth inhibition; ICI 182,780; Tamoxifen

Indexed keywords

ACOLBIFENE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; TAMOXIFEN;

ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME INHIBITION; ESTROGEN ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0037728640     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00068-2     Document Type: Article

References (57)

1. Nicholson R.I., Syne J.S., Daniel C.P., Griffiths K. The binding of tamoxifen to estrogen receptor proteins under equilibrium and non-equilibrium conditions. Eur. J. Cancer. 15:1979;317-329.
2. Bardon S., Vignon F., Derocq D., Rochefort H. The antiproliferative effect of tamoxifen in breast cancer cells: mediation by the estrogen receptor. Mol. Cell. Endocrinol. 35:1984;89-96.
3. Reddel R.R., Murphy L.C., Hall R.E., Sutherland R.L. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Cancer Res. 45:1985;1525-1531.
4. Mouridsen H., Palshof T., Patterson J., Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat. Rev. 5:1978;131-141.
5. Osborne C.K., Yochmowitz M.G., Knight W.A., McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 46:1980;2884-2888.
6. Roseman B.J., Buzdar A.U., Singletary S.E. Use of aromatase inhibitors in post-menopausal women with advanced breast cancer. J. Surg. Oncol. 66:1997;215-220.
7. A.S. Bhatnagar, W.R. Miller, Pharmacology of inhibitors of estrogen biosynthesis, in: G.V.R. Born (Ed.), Handbook of Experimental Pharmacology, vol 135/2. Estrogens, Antiestrogens. Part II: Pharmacology and Clinical Application of Estrogens and Antiestrogens, in: M. Oettel, E. Schillinger (Eds.), Springer-Verlag, Heidelberg, Berlin, 1999, pp. 223-230.
8. Geisler J., King N., Dowsett M., Ottestad L., Lundgren S., Walton P., Kormeset P.O., Lønning P.E. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo amortization and plasma estrogen levels in post-menopausal women with breast cancer. Br. J. Cancer. 74:1996;1286-1291.
9. Smith I.E., Norton A. Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects. Breast Cancer Res. Treat. 49:1998;S67-S71.
10. Miller W.R., Telford J., Love C., Leonard R.C.F., Hillier S., Gundacker H., Smith H., Dixon J.M. Effects of letrozole as primary medical therapy on in situ estrogen synthesis and endogenous estrogen levels within the breast. Breast. 7:1998;273-276.
11. Harper-Wynne C., Dowsett M. Recent advances in the clinical application of aromatase inhibitors. J. Steroid Biochem. Mol. Biol. 76:2001;179-186.
12. Goss P.E., Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol. 19:2001;881-894.
13. Mouridsen H., Gershanovich M., Sun Y.et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for post-menopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. J. Clin. Oncol. 19:2001;2595-2606.
14. Nabholtz A., Buzdar A., Pollak M.et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol. 18:2000;3758-3767.
15. Allegra J.C., Lippman M.E. The effects of 17β estradiol and tamoxifen on the ZR-75-1 human breast cancer cell line in defined medium. Eur. J. Cancer. 16:1980;1007-1015.
16. Katzenellenbogen B.S., Kendra K.L., Norman M.J., Berthois Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short- and long-term absence of estrogens. Cancer Res. 47:1987;4355-4360.
17. Vignon F., Bouton M.-M., Rochefort H. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem. Biophys. Res. Commun. 146:1987;1502-1508.
18. Freiss G., Puech C., Vignon F. Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells. Mol. Endocrinol. 12:1998;568-579.
19. Salerno M., Sisci D., Mauro L., Guvakova M.A., Ando S., Surmacz E. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int. J. Cancer. 81:1999;299-304.
20. Briand P., Lykkesfeldt A.E. Long-term cultivation of a human breast cancer cell line, MCF-7, in a chemically defined medium: effect of estradiol. Anticancer Res. 6:1986;85-90.
21. Briand P., Lykkesfeldt A.E. Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res. 44:1984;1114-1119.
22. Briand P., Petersen O.W., van Deurs B. A new diploid non-tumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium. In Vitro Cell. Dev. Biol. 23:1987;181-188.
23. Briand P., Nielsen K.V., Madsen M.W., Petersen O.W. Trisomy 7p and malignant transformation of human breast epithelial cells following epidermal growth factor withdrawal. Cancer Res. 56:1996;2039-2044.
24. Jakowlew S.B., Breathnach R., Jeltsch J.M., Masiakowski P., Chambon P. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell lines MCF-7. Nucl. Acids Res. 12:1984;2861-2878.
25. 1-antitrypsin and the gene for the S variant. Biochemistry. 23:1984;4828-4837.
26. King C.R., Kraus M.H., Aaronson S.A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 229:1985;974-976.
27. Laborda J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucl. Acids Res. 19:1991;3998.
28. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51:1991;3867-3873.
29. Howell A., DeFriend D., Robertson J., Blamey R., Walton P. Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet. 345:1995;29-30.
30. Simard J., Labrie C., Bélanger A., Gauthier S., Sigh S.M., Merand Y., Labrie F. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D. Int. J. Cancer. 73:1997;104-112.
31. F. Labrie, C. Labrie, A. Bélanger, et al., Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities, in: E.M. Scolnick, F.M. Richards, D.S. Eisenberg, P.S. Kim (Eds.), Advances in Protein Chemistry: Drug Discovery and Design, vol. 56. Academic Press, San Diego, CA, 2001, pp. 293-368.
32. Daniel P., Gaskell S.J., Bishop H., Chambell C., Nicholson R.I. Determination of tamoxifen and biologically active metabolites in human breast tumors and plasma. Eur. J. Cancer. Clin. Oncol. 17:1981;1183-1189.
33. R-1. Cancer Res. 54:1994;1587-1595.
34. Larsen S.S., Madsen M.W., Jensen B.L., Lykkesfeldt A.E. Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. Int. J. Cancer. 72:1997;1129-1136.
35. Larsen S.S., Egeblad M., Jäättelä M., Lykkesfeldt A.E. Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. Breast Cancer Res. Treat. 58:1999;41-56.
36. Foekens J.A., Rio M.C., Seguin P.et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res. 50:1990;3832-3837.
37. Ribieras S., Tomasetto C., Rio M.-C. The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim. Biophys. Acta. 1378:1998;F61-F77.
38. Koos R.D., Banks P.K., Inkster S.E., Yue W., Brodie A.M.H. Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase chain reaction. J. Steroid. Biochem. Mol. Biol. 45:1993;217-225.
39. Thompson E.A., Siiteri P.K. Utilization of oxygen and reduced nicotinamide adenine denucleotide phosphate by human placental microsomes during aromatization of androstenedione. J. Biol. Chem. 249:1974;5364-5372.
40. Howell A., Osborne C.K., Morris C., Wakeling A.E. ICI 182,780 (Faslodex™): development of a novel, "pure" antiestrogen. Cancer. 89:2000;817-825.
41. Horwitz K.B., McGuire W.L. Nuclear mechanisms of estrogen action: effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J. Biol. Chem. 253:1978;8185-8191.
42. Dauvois S., Danielian P.S., White R., Parker M.G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U.S.A. 89:1992;4037-4041.
43. R-6. Br. J. Cancer. 79:1999;386-392.
44. MacGregor Schafer J.I., Liu H., Tonetti D.A., Jordan V.C. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. Cancer Res. 59:1999;4308-4313.
45. Masiakowski P., Breathnach R., Bloch J., Gannon F., Krust A., Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucl. Acids Res. 10:1982;7895-7903.
46. Laursen I., Briand P., Lykkesfeldt A.E. Serum albumin as a modulator on growth of the human breast cancer cell line, MCF-7. Anticancer Res. 10:1990;343-352.
47. Ignar-Trowbridge D.M., Nelson K.G., Bidwell M.C.et al. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 89:1992;4658-4662.
48. Aronica S.M., Katzenellenbogen B.S. Stimulation of ER-mediated transcription and alteration in the phosphorylation state of the rat uterine ER by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol. Endocrinol. 7:1993;743-752.
49. Arnold S.F., Obourn J.D., Jaffe H., Notides A.C. Phosphorylation of the human ER by mitogen-activated protein kinase and casein kinase. Part II: Consequence on DNA binding. J. Steroid Biochem. Mol. Biol. 55:1995;163-172.
50. Kato S., Endoh H., Masuhiro Y.et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494.
51. Pietras R.J., Arboleda J., Reese D.M.et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 10:1995;2435-2446.
52. Bunone G., Briand P.-A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:1996;2174-2183.
53. Weigel N.L., Zhang Y. Ligand-independent activation of steroid hormone receptors. J. Mol. Med. 76:1998;469-479.
54. Knabbe C., Lippman M.E., Wakefield L.M.et al. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell. 48:1987;417-428.
55. Huynh H., Yang X., Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J. Biol. Chem. 27:1996;1016-1021.
56. Chalbos D., Philips A., Rochefort H. Genomic cross-talk between the estrogen receptor and growth factor regulatory pathways in estrogen target tissues. Sem. Cancer Biol. 5:1994;361-368.
57. de Cupis A., Favoni R.E. Estrogen/growth factor cross-talk in breast carcinoma: a specific target for novel antiestrogens. TIPS. 18:1997;245-251.